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Montserrat GuerraAbstract
I was honored to be awarded the Casey Holter Essay Prize in 2013 by the Society for Research into Hydrocephalus
and Spina Bifida. The purpose of the prize is to encourage original thinking in a way to improve the care of
individuals with spina bifida and hydrocephalus. Having kept this purpose in mind, I have chosen the title: Neural
stem cells, are they the hope of a better life for patients with fetal-onset hydrocephalus? The aim is to review and
discuss some of the most recent and relevant findings regarding mechanisms leading to both hydrocephalus and
abnormal neuro/gliogenesis. By looking at these outcome studies, it is hoped that we will recognize the potential
use of neural stem cells in the treatment of hydrocephalus, and so prevent the disease or diminish/repair the
associated brain damage.
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Background
Fetal-onset hydrocephalus is one of the most challenging
pediatric diseases. It has a variety of causes including the
loss of cerebral tissue (cerebral atrophy), the excessive
production of cerebrospinal fluid (CSF), or the obstruc-
tion of CSF pathways due to abnormal neuro- and glio-
genesis [1]. Surgical treatment, such as CSF shunting
and endoscopic third ventriculostomy (ETV) currently
used for the treatment of children with fetal-onset
hydrocephalus, is insufficient. An estimated 50% of
shunts fail within two years and 20-50% of ETVs close
up within five years; infections are also frequent [2].
Additionally, we do not yet know the consequences that
may occur when CSF proteins are shunted into a con-
fined space like the peritoneum that hosts a large num-
ber of immune system cells. There is a high possibility
that shunt surgery and its sequelae generate auto-
antibodies against specific CSF proteins. If these anti-
bodies, or cells that produce them, eventually enter the
brain, they may alter the neuronal physiology and ex-
acerbate neurological deficits. Concerning ETV, we do
not know the consequences of creating an opening
through the membranous floor of the third ventricle toCorrespondence: monserratguerra@uach.cl
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unless otherwise stated.divert CSF into the subarachnoid space. Considering
that the floor of the third ventricle is a highly specialized
region for the secretion of regulatory factors affecting
pituitary activity, ETV may possibly produce adverse
effects on neuroendocrine regulation. It may also divert
signaling molecules in the CSF away from their intended
targets.
Several relatively recent publications have highlighted
the importance and availability of appropriate secreted
proteins (e.g. sonic hedgehog, insulin growth factor) and
non-proteins (e.g. retinoic acid) distributed in the CSF,
and their roles in development and maintenance of brain
health [3-7]. Changes in CSF composition have a pro-
found influence on the development and function of the
brain. So, hydrocephalus, and the treatments available
(shunting, ETV, and cauterizing the choroid plexus) may
limit the availability of these positive factors for the de-
veloping and adult brain, resulting in severe life-long
neurological deficits.
The financial and emotional costs of treatments to pa-
tients and their families are high and additional therapies
are necessary. From where should solutions come? Con-
sidering the advances in medical science, these solutions
will likely come from the more complete knowledge of
the cellular and molecular processes that lead to the
development of the disease [8]. They should come from
laboratories where research generates information to behis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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experimental and clinical investigators is fundamental and
necessary to advance the search for new treatments.
A question emerges: What have we learned about
fetal-onset hydrocephalus from laboratories? This review
aims to show and discuss some of the most relevant re-
cent findings regarding the mechanisms leading to both
hydrocephalus and abnormal neuro/gliogenesis. It is fo-
cused on congenital hydrocephalus attributed to an ob-
struction in CSF pathways as consequence of abnormal
neural stem/radial glial cell biology.
Fetal-onset hydrocephalus is a pathology of neural
stem cells
It is now accepted that fetal-onset hydrocephalus is
more than a disorder of CSF dynamics. It is also a brain
disease. Recent studies have shown that hydrocephalus
and abnormal neurogenesis, observed in both mutant
animals and human hydrocephalic fetuses, share a com-
mon history: a pathology of the neural stem cells (NSC)/
radial glial cells which are located in the ventricular zone
(VZ) during embryonic development [9-12]. In the non-








Figure 1 A representation of normal cortical development showing th
The phenotype of cells located in the ventricular zone (VZ) changes during
glial/neural stem cells and ependyma leads to the disruption of the VZ. In
the subventricular zone (SVZ) occurs from embryonic day (E) 12.5 onward,
the cerebrospinal fluid (CSF) during embryonic development. A timeline co
embryonic days (E) and in human with gestational age in weeks (GA) has b
[68,69]. PN, postnatal; As, astrocytes.and gap junctions (Figure 1). In hydrocephalus, cell-cell
junction proteins accumulate abnormally in the cytoplasm
of NSCs and ependymal cells and depending on the brain
developmental stage it lead to their detachment from the
VZ [10-12]. Disruption of the VZ may also be caused ei-
ther by infections or intracerebral haemorrhage [13]. Only
in a minority of cases is it associated with Mendelian in-
heritance, with X-linked hydrocephalus as the most com-
mon type [14,15].
In hydrocephalus disruption of the VZ is orderly and
programmed. The disruption process starts early in the
embryonic life and finishes during the first postnatal
weeks (Figure 1, red arrow). In the mutant hyh mice the
VZ disruption follows a caudo-rostral specific spatio-
temporal pattern [16-18]. At the end of development
certain regions are denuded of ependymal and subepen-
dymal cells, and other areas are not. The latter corres-
pond to brain areas in which cells are joined by tight
junctions, such as the circumventricular organs (e.g.
subcommissural organ, choroid plexus, etc.). Disruption
is clearly related to the clinical outcome (Figure 2).
Various studies have consistently shown VZ disruption









e timed disruption of the ventricular zone in mouse (red arrow).
normal brain development. Cell-cell junction pathology in the radial
mouse, the exposure of the neural progenitor cells (NPC) localized in
when neurogenesis has been initiated. Note that the VZ cells contact
mparing neurogenesis events in the cortex of the mouse and rat in
een drawn, using a statistical model developed for Clancy et al.
Bleeding/hemorrhage
(intraventricular or cerebral) Viral infection
Cell-cell junction proteins
Abnormal trafficking of 
proteins to membrane
Disruption of the ventricular zone 
(NSCs, ependymal cells)
Hydrocephalus Abnormal neuro/gliogenesis
Loss of cerebral tissue Excessive production of CSF
Figure 2 Clinical outcome is related to the disruption of the
ventricular zone. The disruption of the ventricular zone (VZ)
through effects on cell junction proteins can result from a variety
of causes including abnormal trafficking of proteins to membrane,
bleeding/hemorrhage and viral infections. The disruption of
the ventricular zone in the telencephalon leads to abnormal
neurogenesis. The disruption of the ventricular zone in the Sylvian
aqueduct leads to aqueduct obstruction and hydrocephalus.
Hydrocephalus may also result from loss of cerebral tissue (cerebral
atrophy) and excessive production of cerebrospinal fluid (CSF).
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[10-12,20,21].
What are the consequences of the disruption of the VZ?
Disruption of the VZ in the walls of the Sylvian aqueduct
(SA) leads to SA stenosis during the prenatal life
through fusion of the neuropil and results in SA obliter-
ation prior to birth [16-19] (Figure 2). This finding is
significant since it explains the addition of intraventricu-
lar obstruction after birth to what appeared (by imaging)
to be communicating hydrocephalus pre-birth because
the VZ disruption is only completed post-birth with the
expected consequences [19].
The disruption of the VZ in the pallium and the gan-
glionic eminences leads to disturbances in neuro/glio-
genesis, such as the displacement of neural progenitors
(NPC) towards the CSF and the abnormal migration of
neuroblasts in the cerebral cortex (Figure 2). This results
in periventricular heterotopias (PH) that disrupt the nor-
mal organization and function of the cerebral cortex
[10-12,20,21]. Since these cerebral malformations are
present at birth, it may explain why a large number of
hydrocephalic children develop neurological disorders
(sensory, cognitive sequels, epilepsy) that are not re-
solved by CSF shunting [2].
PH represents a heterogeneous group of migrational
disorders, characterized by nodules that are composed
of neurons positioned ectopically along the lateral ven-
tricular walls; they also behave as epileptogenic foci [22].Prior studies have demonstrated an X-linked form of PH
caused by mutations in the filamin A gene [23,24]. Mu-
tations in other proteins, like ARFGEF2, CHS1, FAT4,
coding for proteins involved in neuronal migration also
lead to PH [23-25]. PHs are also a recurrent, but some-
times inconsistent, finding in terminal deletions of
chromosome 6q [26]. PH associated with hydrocephalus
(PHH) has primarily been reported in sporadic cases
[10-12,21,23]. Genetic and molecular studies suggest
that PHH is an etiologically heterogeneous condition
that can be caused by different genes. One of these is
the NAPA gene, coding for SNAPs (soluble NSF-
attachment proteins) involved in the trafficking of pro-
teins to the apical membrane [21,23,27].
It is estimated that epilepsy affects 6 to 30% of hydro-
cephalic patients [28,29]. However, no correlations have
been found between the number of shunt revisions or
the site of shunt placement and the risk of developing
seizures [30,31]. It seems the most likely explanation for
the development of seizure disorder in hydrocephalic pa-
tients is the presence of associated malformations (PH?)
in the cerebral cortex. Evidence indicating that PH may
result from radial glial/NSCs fiber disruption during em-
bryonic development has been reported [10-12,21,32].
Is stem cell therapy an alternative treatment for children
with fetal-onset hydrocephalus?
Because disruption of the VZ is genetically determined
and its consequences are widespread, the questions that
arise are: is it possible to reverse this process and in
doing so, will it have therapeutic benefits? The available
evidence provides a ray of hope that it is possible to de-
velop regenerative therapies based on the use of NSCs.
These cells have two basic characteristics: they are self-
sustaining and pluripotent [33,34]. This means that they
proliferate for self-renewal; they also have the potential
to differentiate into several cell types within the brain.
There are at least five advantages of using NSCs for
nervous system repair strategies: NSCs are available in
the embryonic and adult brain; they can be transplanted;
and they migrate, differentiate and integrate into dam-
aged areas. Furthermore, studies have shown that the
ability of NSCs to migrate and differentiate into the re-
quired cell type depends on the damaged areas which re-
lease specific chemotactic factors [33,34]. Regenerative
therapies are being used in the treatment of various
neural disorders such as Parkinson’s and Alzheimer’s
disease and multiple sclerosis [35-37] (Table 1).
According to these studies and the revealed character-
istics of NSCs a hopeful light is emerging for the future,
so healthy NSCs can be transplanted into CSF to replace
radial glial cells, neural progenitors and neuroblasts that
are lost during the hydrocephalic process. This regenera-
tive therapy might well repair the VZ and/or reverse the
Table 1 Clinical use of stem cells in the nervous system
Pathology References
Alzheimer’s Disease Abdel-Zalam et al., 2011 [87]
Parkinson’s Disease Bjugstad et al., 2008 [88]
Huntington’s Disease Mc Bride et al., 2004 [89]
Multiple sclerosis Pluchino et al., 2003 [90]; Martini et al., 2010 [54];
Rivera and Aigner 2012 [56]
Spinal cord injury Obermair et al., 2008 [91]
Brain stroke Kelly et al., 2004 [92]
Cerebral palsy Cheng et al., 2013 [55]
Spina bifida aperta Fauza et al., [77]; Li et al., 2012 [57]
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cerebral cortex that are found in the hydrocephalic chil-
dren, which until now have been considered incurable,
could have a realistic and promising alternative treat-
ment. Such research could also open new ways to
identify genes and epigenetic factors (growth factors,
hormones) involved in neuronal and glial phenotypic dif-
ferentiation allowing the design of new drugs to regulate
the normal development of the cerebral cortex.
Stem cell therapy for hydrocephalic children: is it science
fiction or fact?
The development of regenerative therapies based on the
use of NSCs to treat children with hydrocephalus is
advancing well. Research led by Dr. EM. Rodríguez in
Valdivia, Chile, using HTx hydrocephalic rats that re-
ceive transplants with NSCs, today represents the most
advanced and promising alternative treatment for chil-
dren with fetal-onset hydrocephalus. Preliminary studies
have demonstrated that NSCs transplanted into CSF of
hydrocephalic HTx rats at postnatal day 1 migrate to the
disrupted areas and are integrated into nervous tissue
[Rodríguez et al., unpublished work]. The effect of this
grafting on neuro/gliogenesis is under current investiga-
tion. The optimal timing for potential NSC transplant-
ation into human CSF is unknown at this time. With the
different causes leading to hydrocephalus in mind, a pro-
posed stem cell therapy would have to be adapted to the
different clinical backgrounds.
Investigations in Chile have already borne fruit. NSCs
collected from the CSF of hydrocephalic mutant rats
and hydrocephalic human fetuses proliferate to form
neurospheres (Figure 3). NSCs forming these neuro-
spheres express the same cell junctional pathology as
NSCs of pallium (Figure 3) [Rodríguez et al., unpub-
lished work]. These accomplishments open the door for
the use of neurospheres for diagnostic purposes, such as
brain biopsies to investigate cell and molecular alter-
ations underlying the disease. In this context, it is signifi-
cant to note that although nearly 40% of hydrocephaluspatients have a possible genetic cause, to date only the
L1-CAM gene has been identified in humans [15].
It is worth noting that although sphere formation has
been extensively utilized by research groups as an assay
for stem cells to isolate, maintain, and expand NSCs
[38], like all technologies, it is not without limitations,
some of which have been extensively reviewed by differ-
ent authors [39-41]. Furthermore, the growth and differ-
entiation of neurospheres depend on cell culture density,
the clonality of spheres and the presence of exogenous
growth factors such as epidermal growth factor (EGF) or
fibroblast growth factor (FGF) [39-41]. While new assays
and markers for stem cells and their progeny have yet to
be developed to overcome some of the limitations of the
neurospheres assay, these have to be kept in mind before
extrapolating results or translating the experimental
transplantation of neurosphere-derived cells to the clin-
ical setting.
What will be the source of NSCs to be transplanted?
Today it is well known that NSCs are present in the em-
bryonic and adult brain. During embryonic development,
the NSCs are in the VZ whereas during adulthood there
are “neurogenic niches” where specific postnatal neurogen-
esis persists. Postnatal neurogenesis in these areas is associ-
ated with the renewal of the olfactory epithelium, memory
formation and cerebral metabolic homeostasis [42].
Human embryonic stem cells (hES cells)
These pluripotent cells have a major clinical potential
for tissue repair, with their proponents believing that
they represent the future relief or cure for a wide range
of common disabilities [43,44]. It is suggested that the
replacement of defective cells in a patient by transplant-
ation of hES cell‐derived equivalents would restore nor-
mal function. Recently they have been used to generate
choroid plexus (CP) cells [45]. Because of the essential
developmental and homeostatic roles of CP cells relating
to the CSF and the resulting blood-CSF barrier, the
transplant of hES cells into CSF and differentiation into
CP cells could represent a new approach for developing
a therapy for hydrocephalus. Interestingly, CP cells have
been grafted into the lateral ventricle of normal and
hydrocephalic HTx rat littermates [Rodríguez et al., un-
published work]. One week after transplantation the
transplanted CP retained the cellular and molecular
characteristics of living CP such as the expression of
transthyretin in the cytoplasm and aquaporin1 at the ap-
ical plasma membrane. Since the grafted CP cells did
not become re-vascularized, they would not secrete CSF
but could be an extra source of trophic factors.
Despite the potential benefit of using hES cells in the
treatment of disease, their use remains controversial be-












Figure 3 Neurospheres can be grown from the cerebrospinal fluid of hydrocephalic HTx rats. The disruption of the ventricular zone (VZ)
leads to the abnormal translocation of neural stem cells (NSC) and neural progenitor cells (NPC) into the ventricle [10,11]. A. Coronal section of
hydrocephalic brain stained with haematoxylin-eosin. Cells collected from the cerebrospinal fluid (CSF) of hydrocephalic HTx rats at postnatal day
1 (PN1) were cultured in medium containing 20 ng/ml epidermal growth factor (EGF) for six days. BrdU was added to the culture medium for the
last 24 h. B-D. Immunofluorescence of large and small neurospheres with anti-BrdU stain showing proliferative (NSC/NPC) cells. C. High magnifica-
tion of a small neurosphere. D. High magnification of a large neurosphere. E. After 6 days in vitro neurospheres had an irregular outline, with cells
“disrupting” from its periphery (arrows) resembling that of the VZ of the living mutant. DIC, Differential interference contrast microscopy. Scale
bars: A 600 μm; B 50 μm; C 5 μm; D, E 10 μm.
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the transfer of a somatic cell‐nucleus from a patient to
an enucleated oocyte (unfertilized egg) in order to pro-
duce hES cells genetically identical to that patient for
‘autologous’ transplantation (so‐called ‘therapeutic’ clon-
ing) which avoids tissue rejection [47,48]. hES cells are
currently discussed not only by the biologists by whom
they were discovered but also by the medical profession,
media, ethicists, governments and politicians. The ques-
tion ‘Can these cells be isolated and used and, if so,
under what conditions and restrictions?’ is presently
high on the political and ethical agenda, with policies
and legislation being formulated in many countries to
regulate their derivation.
Mesenchymal stem cells (MSCs)
Fortunately, the use of embryos is not the only and
best way to obtain stem cells. Populations of stem cellsreside within different tissues, representing an alterna-
tive source of cells that can be harvested at low cost, iso-
lated with minimal invasiveness, and without ethical
objections, are emerging as a replacement for hES cells
[49]. In this context, various studies have shown the
presence of a large MSCs population in umbilical cord
blood, placental membranes and amniotic fluid [50]. In
human and veterinary research, stem cells derived from
these tissues are promising candidates for disease treat-
ment, specifically for their plasticity, their reduced
immunogenicity, and high anti-inflammatory potential
[51-53]. Increasing research of molecular mechanisms
that drive the differentiation of MSCs to NSCs [54,55]
enhance the likelihood that MSCs could be useful in the
treatment of neurological diseases. In fact, already trans-
plantation of MSCs promotes myelin repair and func-
tional recovery in different animal models of multiple
sclerosis [56]. Transplantation also confers beneficial
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fetuses with spina bifida [57].
Induced pluripotent stem cells (iPSCs)
Today, thanks to progress in the ability to manipulate
cell identity, it is possible to reprogram adult skin fibro-
blasts into induced pluripotent stem cells (iPSCs). They
represent a new tool for drug discovery, disease model-
ing and a new hope for stem cell therapies [58-62]. In a
recent paper Lancaster et al. [63] described a method
for growing three-dimensional neural tissue from human
PSCs and used it to model microcephaly. The resulting
cerebral organoids reached up to 4 mm in size and con-
tained polarized radial glia-like stem cells that surround
a fluid-filled cavity resembling the lateral ventricle in the
developing brain. This model may serve as a valuable
in vitro platform for studying the molecular mechanisms
that regulate the development of brain cortex and could
provide an innovative and complementary approach for
the study of the VZ disruption leading to hydrocephalus
and abnormal neuro/gliogenesis in vitro.
When should NSC transplantation be performed?
The hyh mutant mouse develops long-lasting hydro-
cephalus and is a good model for investigating neuro-
pathologic events associated with hydrocephalus. The
study of brains using lectin-binding, bromodeoxyuridine
labeling, immunochemistry, and scanning electron mi-
croscopy has revealed that certain events related to
hydrocephalus follow a well-defined pattern [16-18]. A
program of VZ disruption is initiated at embryonic day
(E)12.5 at the cerebral aqueduct and terminates at the
end of the second postnatal week at the telencephalon.
After the third postnatal week the disrupted areas re-
main permanently devoid of ependyma. The etiopatho-
genesis of hydrocephalus in the HTx rat is different
from that in the hyh mouse. A distinct malformation of4     8    12    16    20   24    28   32   36 
Bi
Gestation (weeks) 
Figure 4 Timeline of major events in the human brain development f
proliferation; Green bar, neural migration; Red bar, myelination; Orange barthe subcommissural organ (SCO) is present as early as
E15 leading to stenosis of the cerebral aqueduct at E18
and dilation of the lateral ventricles starts at E19 [64,65].
At this stage, the VZ disruption is initiated in the
pallium of telencephalon and terminates at the end of
the first postnatal week.
In hydrocephalic human fetuses the VZ cells, either NSCs
or ependymal cells, undergo disruption [10-12,19,20]. In
young hydrocephalic fetuses (21, 22 weeks of gestational
age, GA) disruption occurs in the pallium while in 40-week
GA fetuses the disruption extended to other regions of the
lateral ventricles. The VZ disruption in the pallium was
found to be related to the presence of PHs in the telenceph-
alon and the abnormal displacement of the NSCs into the
ventricle [10-12,20]. In full-term hydrocephalic fetuses with
spina bifida aperta (37-, 39-and 40-week GA), both early
and late stages of the VZ disruption were concurrently
present in the cerebral aqueduct [19] indicating that at
these stages, the VZ disruption is still an ongoing process.
In these fetuses it may be suggested that such a process
would have continued after birth. Only when this program
is completed, the obliteration of SA occurs, triggering a se-
vere hydrocephalus [19].
Human brain development is a protracted process that
begins in the third gestational week [66,67]. Neuron pro-
liferation begins in the sixth gestational week and is
largely complete by mid-gestation. As they are produced,
neurons migrate to different brain areas where they
begin to make connections with other neurons establish-
ing rudimentary neural networks. Although at the end
of the prenatal period major fiber pathways, including
the thalamocortical pathway, are complete, brain devel-
opment continues for an extended period postnatally
(Figure 4).
So far, the information obtained from mutant animals
and human hydrocephalic fetuses strongly supports
the idea that pallial disruption occurs while corticalAdulthood 
rth 
rom conception through to adulthood. Blue bar, neuronal
, synaptogenesis; Purple bar, apoptosis (adapted from [93]).
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plants should be done when the VZ disruption occurs.
In this context, NSC transplantation should occur in the
early stages of fetal development during the process of
neuron production in the cortex [66-69]. There are rea-
sons to be optimistic. Recent progress made with fetal
surgery in utero [70,71] allows us to foresee that these
surgeries might become increasingly safe and that trans-
plantation of NSCs in utero might become feasible. The
main priority must be maternal and fetal safety and
avoiding preterm labor while achieving the aims of the
surgery [72]. Open fetal surgery is possible between ap-
proximately 18 and 30 weeks of gestation: the limitations
being fetal size and fragility before 18 weeks and, and
increased risk of premature labor after 30 weeks [72].
Clearly it would be preferable to deliver the child and
perform surgery ex utero instead. Prenatal repair of
neural tube defects such as myelomeningocele and spina
bifida is an increasing option in the United States.
Although the procedure is technically challenging, chil-
dren treated with open fetal repair have significantly im-
proved outcomes compared to children whose defects
are repaired shortly after birth [73,74]. Specifically, fetal
repair reduces the rate of ventriculoperitoneal shunt de-
pendence for hydrocephalus and improves motor skills
at 30 months of age compared to those with post-natal
repair. As a result, open fetal repair of spina bifida is
now considered standard of care at specialist centers.
Most children born with spinal bifida also have hydro-
cephalus. Why not use open fetal surgery to repair the
neural tube defects as an opportunity to transplant
NSCs? Indeed, fetal cell therapies have been employed
in the treatment of human congenital hematological dis-
eases and immunodeficiency [75,76], and in experimen-
tal animal models of spina bifida and myelomeningocele
[57,77]. These studies have also shown that the safety of
stem cell therapy depends on various factors including
the differentiation status and proliferative capacity of the
grafted cells, the route of administration and the long-
term survival of the graft.
What should we expect of repair?
It was first assumed that stem cells directly replace lost
cells, but it is now becoming clearer that they might be
able to protect the nervous system through mechanisms
other than cell replacement, such as the modulation of
the immune system [51-53,78,79]. Worthy of note is the
remarkable capacity of NSCs and NPCs to cross-talk
with endogenous cells and to remodel the injured ner-
vous system when they are applied [80-83]. Further, a re-
cent study demonstrated an astrocytic reaction in the
disrupted VZ in hydrocephalus in that astrocytes acquire
morphological and functional characteristics of epen-
dymal cells, suggesting that they function as a CSF–brain barrier involved in water and solute transport [84].
Such remodeling would help to re-establish lost func-
tions at the brain parenchyma–CSF interface. Therefore,
we postulate that grafting of NSCs into hydrocephalic
brain would result in the replacement of cells and/or the
generation of a protective microenvironment to prevent
the progressive disruption of the VZ and to enhance fa-
vorable glial responses.Conclusions
Today it is accepted that fetal-onset hydrocephalus is
more than just an alteration in CSF dynamics. It is also a
brain disorder. Children born with hydrocephalus also
have a severe malformation of the cerebral cortex and
cognitive deficits. These deficiencies are not successfully
addressed by shunting or by ETV. The transplantation
of NSCs is emerging as a great hope to correct brain
maldevelopment, helping to reduce the brain damage
and promoting regeneration and repair through direct
cell replacement and neurotrophic and immunomodula-
tory mechanisms. Many questions regarding the applica-
tion of stem cells remain unanswered, particularly
tumorigenicity, immune rejection and danger of gene
manipulation. However, transplantation is expected
eventually to become as common a practice as other
treatments for neurological diseases ([85,86], Table 1).
To achieve the NSCs transplantation goal for hydro-
cephalus/spina bifida will require better integration of
experimental and clinical activities to reveal the genetic
control of identity and growth of stem cells, identify fac-
tors that predispose differentiation into specific neuronal
or glial lineages, and implement surgical techniques that
allow safe NSCs transplants. Expectations, though
guarded, are high. If both basic and clinical researchers
join forces, the dream of providing a better life to chil-
dren with hydrocephalus will draw closer with each
passing day.
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